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Humanized mice offer a great platform to study human diseases in vivo and to 
test new therapies. Although much progress has been made to improve human 
hematopoietic cell engraftment by generating new strains of immunodeficient 
mice, the limited number of hematopoietic stem cells (HSCs) in a single unit 
of cord blood, and the poor reconstitution and function of human 
monocytes/macrophages still remain as major limitations in current non-obese 
diabetic (NOD) /scid IL-2rg-/- mice (NSG mice).  
To overcome these two problems, we first developed a robust HSC co-culture 
system wherein cord blood CD133+CD34+ cells were co-cultured with 
mesenchymal stem cell (MSC) engineered to express angiopoietin-like-5 
(Angptl5) in cytokine supplemented media. The number of double positive 
(DP) cells was expanded around ~60 fold after 11 days in this culture system, 
and expanded cells were capable of long-term engraftment in NSG mice. 
Further, the expanded cells supported multilineage reconstitution of human 
blood cells in NSG mice, including a more efficient T cell reconstitution. With 
this expansion method, large-scale experiments with humanized mice 
reconstituted with cord blood HSCs become possible, and the variation among 
different donors could be minimized.  
The poor engraftment and function of human macrophages in NSG mice were 
corrected by a single injection of plasmid encoding human macrophage 




human cells, we identified that the human macrophage development was 
blocked at promonocyte stage in the bone marrow (BM) of NSG mice. This is 
unexpected because M-CSF is believed to play a role at a much earlier stage in 
mouse macrophage development. After the induction of human macrophages 
by human M-CSF, we observed engraftment of human macrophages in 
various organs, such as liver and lung. This is the first direct evidence for 
human tissue macrophage reconstitution in humanized mice. Moreover, these 
human tissue macrophages responded to infections with several natural human 
pathogens in vivo, and were able to slow down disease progression. With the 
engraftment of human tissue macrophages in NSG mice, we not only facilitate 
the study of human macrophages in vivo but also make the humanized mice 
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1.1 Introduction to the humanized mice 
The term ‘humanized mice’ is used to describe several experimental systems. In this 
thesis, it refers to immunodeficient mice with components of the human immune 
system. As a small animal model, humanized mice allow versatile experimentation 
and are easily accessible to the research community. More importantly, the 
knowledge obtained from this model may be more relevant and applicable to humans. 
Because of the differences between human and murine immune systems, the direct 
extrapolation of data from studies of mouse models to the clinic becomes 
complicated, sometime inappropriate. For example, TGN1412, a humanized 
monoclonal antibody binding to CD28 receptor of T cells, was originally developed 
for treatment of B cell chronic lymphocytic leukemia and rheumatoid arthritis. In its 
first clinical trial in 2006, it caused catastrophic systemic organ failure in the treated 
subjects at the administered dose, which was 500 times lower than the dose found safe 
in animal tests (Hansen and Leslie, 2006; Kenter and Cohen, 2006; St Clair, 2008; 
Stebbings et al., 2009; Suntharalingam et al., 2006). In a recent study from our lab, 
cytokine storm similar to what has been reported in clinical trials was observed in 
improved humanized mice (manuscript in preparation). Hence, the humanized mice 
offer a tool to bridge the bench and bed gap without putting the patient into risk.  
Despite calls for humanized mice, the development of a mouse strain permissive for 
good human cell engraftment has been slow. In the past 20 years, the increasing use 
of clinical hematopoietic cell transplantation in genetic malignant diseases and 
immunodeficiencies, as well as the emergence of threatening pandemics caused by 




extremely low human hematopoietic cell reconstitution to a functional immune 
system. Thus, several major breakthroughs in this field are reviewed below.  
1.1.1 The development of humanized mice   
The history of humanized mice began with the discovery of a Prkdcscid mutation 
(protein kinase, DNA activated, catalytic polypeptide; severe combined 
immunodeficiency) mutation in CB17 mice (Bosma et al., 1983). The Prkdcscid 
mutation results in the absence of the catalytic subunit of a DNA-dependent protein 
kinase (Araki et al., 1997; Blunt et al., 1996; Fried et al., 1996; Jeggo et al., 1996; 
Kirchgessner et al., 1995), which plays an indispensable role in activation of a DNA 
recombinase enzyme during V(D)J recombination of lymphocyte antigen receptors 
(Lieber et al., 1988; Malynn et al., 1988; Miller et al., 1995). Hence, this strain of 
mice lacks mature and functional T lymphocytes. This scid mouse model allowed 
only 0.5%-5% human cell reconstitution, but it was already a successful ‘proof of 
concept’. The extremely low levels of human reconstitution are due to the presence of 
relatively intact murine innate immunity (e.g. murine monocytes, macrophages, and 
natural killer cells) and the leakiness of the mutation itself (Bosma et al., 1988; Shultz 
et al., 1995). 
In an effort to overcome the rejection of human graft caused by murine myeloid cells 
and natural killer (NK) cells in CB17-scid mice, the scid mutation was introduced into 
NOD mice, which reached 5-10 fold higher levels of human peripheral blood 
mononuclear cell (PBMC) reconstitution (Hesselton et al., 1995). The improvement in 
NOD/scid mice was thought to be due to additional defects in innate immunity of 
NOD strain. For instance, NOD mice carry a polymorphism in signal regulatory 




prevent the phagocytosis of human cells (Takenaka et al., 2007). The hemolytic 
complement pathways in NOD mice are also inactive due to the specific deficiency of 
C5 complement (Baxter and Cooke, 1993). Moreover, the NOD-scid mice are 
resistant to the leakiness seen in CB17-scid mice, as only 10% of mice have 
detectable immunoglobulin (Ig) in serum at 6 months of age compared to 90% of 
CB17-scid mice at the same age (Shultz et al., 1995). Hence, the NOD/scid mice 
became the gold standard for human cell engraftment studies and were widely used as 
xenotransplant recipient mice since 1995. The usefulness of this model, however, is 
limited by the short life span caused by the development of fatal thymic lymphomas 
around 8 months old (Prochazka et al., 1992; Shultz et al., 1995). In addition, 
although the engraftment of human cells is much improved in NOD/scid mice, high 
levels of human cell engraftment are still not seen. This is likely due to remaining NK 
cell activity in NOD/scid mice (Greiner et al., 1998). 
To increase further the engraftment of human cells, several methods to genetically 
block the development of NK cells were tested. One major success was achieved in 
2005, when Shultz and colleagues back-crossed immunodeficient mice lacking the 
gene for the common cytokine-receptor  chain to the NOD/scid mice to create 
NOD/scid IL-2rg-/- (NSG) mice (Ishikawa et al., 2005; Shultz et al., 2005). The 
common  chain is a critical component for interleukins (IL) 2, 4, 7, 9, 15, 21 
receptors (Asao et al., 2001; Sugamura et al., 1996). These cytokines play myriad 
roles in differentiation, maturation, activation and homeostasis of T cells (IL-2, IL-7 
and IL-15), B cells (IL-7, IL-21), and NK cells (IL-2, IL-15) (Janeway, 2001; 
Kovanen and Leonard, 2004). As a result of this deficiency, not only mouse T and B 
cells, but also NK cells do not develop in NSG mice (Shultz et al., 2005). The average 




NOD/scid mice (Shultz et al., 2005). Furthermore, NSG mice are free of thymic 
lymphomas, which increase the lifespan from 37 weeks in NOD/scid mice to 90 
weeks in NSG mice (Shultz et al., 2005). This much longer life span makes long-term 
experiments possible, especially for HIV studies. It is NSG mice reconstituted with 




1.1.2 Remaining issues of humanized NSG mice 
The previous efforts to improve humanized mice specifically aimed for high levels of 
human cell engraftment by the creation of various mouse strains with deficiencies in 
mouse immunity. This goal has been fulfilled by the creation of NSG mice. The 
current focus of humanized mice switched to establishing a functional human immune 
system and using this model for preclinical and clinical applications. Several critical 
issues that need to be addressed in order to achieve this aim will be discussed below:  
1.1.2.1 Stable reconstitution and the availability of human HSC  
At least 1x105 human CD34+ cells are needed to achieve >10% reconstitution in 
newborn pups or in adult NSG mice, and the reconstitution is only stable between 2 to 
12 months. There are too few human cells before 2 months of reconstitution and one 
type of human blood cells, usually human T cells, dominates after 10 months of 
reconstitution. In contrast, single syngeneic mouse HSC could lead to more than 50% 
hematopoietic chimerism for at least 10 months, whereas 10 fold greater numbers of 
mouse HSCs are required for fully major histocompatibility complex (MHC)-
mismatched recipients. In addition, homeostatic expansion of human CD34+ cells is 
not observed in humanized mice, and the frequency of scid repopulating cells (SRC) 
and chimerism decline over time. This evidence suggests that human HSC are not 
maintained in humanized mice (Manz, 2007). This could be due to the difficulty of 
human HSC homing to mouse BM, or the insufficient support from mouse BM 
niches, or the residual mouse immunity against human HSCs. To improve this 
situation, co-transplantation of human MSC (Muguruma et al., 2006) or mouse MSC 
engineered to express human cytokines with human HSCs may benefit the homing 




mouse MHCs or to transiently express certain mouse chemokine receptors may also 
help the homing and long-term reconstitution. Till now, not much progress has been 
made on this issue of humanized mice.  
The common sources for human CD34+ cells are human cord blood, human fetal 
liver, and less frequently, cytokine mobilized adult peripheral blood and adult BM. 
Since the CD34+ cells isolated from adult humans are less effective to reconstitute 
humanized mice, CD34+ cells from cord blood or fetal liver are typically used (Lepus 
et al., 2009). As the availability of human fetal liver is uncertain, and the use of fetal 
samples for research purpose is strictly regulated, many laboratories working with 
humanized mice use cord blood as their routine source for human CD34+ cells. 
However, the number of CD34+ cells isolated from a single unit of cord blood is 
around 0.2-1x106, which is only enough to reconstitute 1-5 newborn pups. The limited 
number of mice produced from one unit of cord blood makes it difficult to set up 
experiments with proper controls. Humanized mice made from different batches of 
cord blood or from pooled human CD34+ cells may be used to increase the number to 
meet the requirement of experiments. However, the results obtained from different 
units of cord blood often make it difficult to draw conclusions because the 
reconstitution kinetics and ability vary among batches (Drake et al., 2011). In 
addition, the purchase of one unit of cord blood and the isolation process typically 
cost several hundred dollars. It would be prohibitively expensive for a lab to generate 
humanized mice routinely with this method. Thus, it would be desirable to expand a 
population of long-term reconstituting human HSCs in vitro so that an entire study or 




1.1.2.2 Unbalanced human hematopoietic cell reconstitution 
8 to 12 weeks after injection, human HSC and progenitor cells differentiate and form 
a human hemato-lymphoid system in NSG mice. Almost all major cell populations of 
the human immune system, including dendritic cells (DC), natural-interferon 
producing cells, T cell, B and Ig-producing cells, could be found in organs and 
peripheral blood of NSG mice. However, the level of human cell reconstitution differs 
significantly among different lineages.  
B cells: Human B cell differentiation in BM of humanized mice seems to resemble 
that in humans since several stages of B cell precursor populations exist, such as early 
B cells, pro-B cells, pre-B cells and immature B cells (Watanabe et al., 2009). 
However, the peripheral mature B cells in humanized mice express high levels of 
CD5 (Matsumura et al., 2003), which is markedly different from human B cells found 
in adult peripheral blood. CD5 was considered a marker for B-1 cells, a minor 
fraction of B cells characterized by three functions: spontaneous IgM secretion, 
efficient T cell stimulation, and tonic intracellular signaling (Griffin et al., 2011). The 
origin and development of B-1 cells are still unclear but evidence suggests that they 
may arise from precursors in fetal liver, and certain antigens are needed to shape the 
repertoire of the B-1 population (Bendelac et al., 2001). Recently, B1 population is 
defined by CD20+CD27+CD43+CD70- in umbilical cord blood and adult peripheral 
blood and the overlap of this population with CD20+CD5+ is only ~34% (Griffin et 
al., 2011). As the majority of B cells in humanized mice are CD5+ B cells, further 
characterization of this population is needed to understand the problem of human B 
cell development.  
T cells: The major achievement in NSG mice is efficient intrathymic de novo human 




cells in NSG mice, including CD4 and CD8 T cells, show a broad V distribution. 
The ratio among CD4 T cells, CD8 T cells, Foxp3+ CD25+ regulatory T cells and 
T cells is quite close to physiological level. The problem for human T cells in 
humanized mice is poor activation and function, not the development or 
reconstitution. That problem will be discussed separately.  
NK cells: NK cells development could be detected in BM as early as 4 weeks after 
HSC transfer in humanized mice. However, the number of peripheral NK cells is 
generally low or undetectable (Chen et al., 2009). The poor reconstitution of human 
NK cells possibly results from inappropriate cytokine cross-reactivity between mouse 
and human (Manz, 2007). In 2009, hydrodynamic injection was used to express 
human IL-15 and Flt-3/flk2 required for NK cell development. This method 
successfully improved the reconstitution and function of NK cells in NSG mice (Chen 
et al., 2009). In other studies, human NK cells were also induced by in vivo 
supplementation of human IL-15/human IL-15R  complex or by transgenic 
expression of human IL-2 in NOG mice (Huntington et al., 2009; Ito et al., 2012).  
Monocytes/Macrophages and DCs: Although monocytes/macrophages and DCs 
develop in humanized mice, their frequencies are usually very low. In a study from 
our lab, expression of human granulocyte-macrophage colony-stimulating factor 
(GM-CSF) /IL-4 and human macrophage colony-stimulating factor (M-CSF) also 
resulted in significantly increased numbers of human DCs and monocytes in 
peripheral blood of humanized mice, respectively (Chen et al., 2009). Similarly, 
monocytes and alveolar macrophages were boosted in M-CSF and GM-CSF/IL-3 
human cytokine knock-in NSG mice, respectively (Rathinam et al., 2011; Willinger et 




mice, except for alveolar macrophages in GM-CSF/IL-3 mice, and in vivo immune 
functions in NSG mice with improved monocyte reconstitution have not been 
reported.  
Granulocytes and erythrocytes: Granulocytes and erythrocytes comprise the largest 
fraction of human hematopoietic cells. These two cell types, however, are the lowest 
reconstituted populations in humanized mice. Several groups attempted to improve 
these two types of cells but without much success. A slight increase in CD15+ 
granulocytes was observed in the BM of stem cell factor (SCF), GM-CSF and IL-3 
transgenic NSG mice (Billerbeck et al., 2011). Some human CD66+ granulocytes also 
were produced in the BM of Thrombopoietin (TPO) knock-in mice (Rongvaux et al., 
2011). In a study from our lab, a low but significant level of human erythrocytes in 
NSG mice could be induced by hydrodynamic injection of plasmid expressing 
erythropoietin (EPO) and IL-3 (Chen et al., 2009). However, the induction took more 
than one month. Collectively, the development of granulocytes and erythrocytes could 
be partially improved by the addition of human cytokines.  
1.1.2.3 Weak antigen specific T cell and B cell responses 
Upon unspecific stimulation, these generated human T cells are capable of 
proliferating and producing cytokines both in vitro and in vivo. However, human T 
cells have a limited ability to respond to antigen stimulation. To understand this 
problem, we have to unravel what MHC is to be expected from human T cells 
educated on a mouse background. As the positive selection of thymocytes 
preferentially occurs on epithelial cells, and no evidence of human thymic epithelial 
cells could be derived from reconstituted CD34+ cells, human thymocytes should be 
positively selected on mouse MHC content. There has been a report of human DCs in 




both epithelial cells and hematopoietic derived DCs. Hence, human thymocytes may 
be negatively selected on both mouse and human MHC content.  
This hypothesis of human thymocyte selection in a mouse thymus was supported by 
the mixed lymphocyte reactions (MLRs), in which human T cells from NSG mice 
proliferated vigorously when stimulated with human allogeneic DCs, but proliferated 
weakly when stimulated with autologous human DCs or mouse DCs (Traggiai et al., 
2004). In addition, we used humanized mice to establish Epstein-Barr virus (EBV) 
and dengue infection models in our lab, but human T cells in mice were unable to 
control the virus replication (unpublished data). There were also studies on influenza 
virus infection in humanized mice. They reported that human T cells specific for viral 
epitopes were only found in the context of mouse MHC (Legrand et al., 2006). Taken 
together, the evidence suggests that human T cells in mice are tolerant for both 
autologous human and mouse MHC. They frequently mount reactions towards 
allogeneic MHC but produce, to some extent, specific responses only in the context of 
autologous mouse MHC.  
As a result of insufficient human T cell responses in vivo, antibody production in 
humanized mice is far from optimal. Human IgG concentration in serum increases 
over the course of reconstitution, and is on average 10-100 fold lower than in human 
adults and wild-type mice (Baenziger et al., 2006; Traggiai et al., 2004). Specific IgG 
responses against tetanus toxoid (TT), ovalbumin, and dinitrophenyl-keyhole limpet 
haemocyanin (DNP-KLH) are very low or undetectable (Baenziger et al., 2006; 
Ishikawa et al., 2005; Traggiai et al., 2004). To enhance the antibody response in 
humanized mice, the key is to establish a robust T cell response to adequately help B 
cells mature into antigen-specific antibody-producing cells. The obvious solution to 




NSG mice with human MHC class I have been created. Cytotoxic human T 
lymphocytes became functionally mature, and mounted human leukocyte antigen 
(HLA)-restricted cytotoxicity against EBV infected human B cells in NSG-HLA-A2 
mice (Jaiswal et al., 2012). However, the antibody response in this mouse was not 
much improved. The NSG-HLA-DR mice and the NSG-HLA/A2-HLA/DR mice are 





1.2 Focus and objectives of this thesis 
Despite high human cell engraftment in humanized NSG mice, those issues discussed 
above greatly hampered its impact and application in basic and applied preclinical 
human immunology research. In this thesis, we only focused on three critical 
problems of humanized mice: 
Limited supply of human cord blood HSCs and variations from small 
cohorts of cord blood HSCs in reconstituted humanized mice 
Chapter 3 describes the efforts to develop a method for HSC expansion in vitro. Four 
goals were addressed: 1) Establish and optimize the conditions for human HSCs 
expansion. 2) Evaluate and compare the differentiation potential of expanded HSCs 
into hematopoietic lineages in NSG mice. 3) Evaluate the long-term reconstitution 
potential of expanded HSCs. 4) Investigate the functions of human immune system in 
humanized mice engrafted with expanded HSCs.  
Poor understanding of human macrophage development and no tissue 
macrophage reconstitution in humanized mice 
Chapter 4 shows the efforts to generate human monocytes/macrophages in humanized 
mice. Four goals were addressed 1) Investigate the problem of human 
monocyte/macrophage development in humanized mice. 2) Develop methods to 
restore the monocyte/macrophage population in peripheral blood and tissues of 
humanized mice. 3) Test the functions of induced monocytes/macrophages. 4) 
Evaluate the innate immunity in humanized mice with improved 





Weak antigen specific antibody response in humanized mice 
Chapter 5 shows the efforts to increase antigen specific antibodies in humanized mice. 















2.1 Stem cell purification 
Purified human CD133+ cord blood cells were purchased from AllCells (California). 
Alternatively, umbilical cord blood was obtained from the Singapore Cord Blood 
Bank. Red blood cells (RBCs) were removed by Ficoll-Hypaque density gradient.  
Human fetal liver samples were obtained from aborted fetuses at 15-23 weeks of 
gestation, in accordance with the institutional ethical guidelines of the National 
University Hospital of Singapore. All women gave written informed consent for the 
donation of their fetal tissue for research. Fetuses were collected within 2 h of the 
termination of pregnancy. A single cell suspension was prepared. To isolate human 
CD34+ cells, fetal liver samples were excised into small pieces and digested with 
collagenase IV (2 mg/ml) at 37 °C for 15 min. A single cell suspension was prepared 
by passing the digested tissue through a 100 m cell strainer (BD Biosciences).  
CD34+ cells were purified with the RosetteSep system using the CD34 positive 
selection kit (Stem Cell Technologies, Vancouver, BC). The purity of purified cells 
was 90 to 99% CD34+. On average, 95% of the purified CD34+ cord blood cells, and 
30% of purified CD34+ fetal liver cells were also CD133+ (data not shown). 
Following in vitro expansion, CD133+ cells were purified by staining cells with PE-





2.2 Feeder cell-free (FCF) culture of cord blood CD34+CD133+ cells 
Cryopreserved or freshly isolated CD34+CD133+ cord blood cells were cultured in 
vitro as described (Zhang et al., 2008). Briefly, StemSpan medium (Stem Cell 
Technologies, Vancouver) were supplemented with 20 ng/ml SCF (R&D), 10 ng/ml 
TPO (R&D), 10 ng/ml fibroblast growth factors-1 (FGF-1) (Gibco), 100 ng/ml 
Insulin-like growth factor-binding protein 2 (IGFBP2) (R&D), 500 ng/ml 
angiopoietin-like 5 (Angplt5) (Abnova, Taiwan), 500 µg/ml of heparin (Sigma), 1x 
penicillin and streptomycin (Gibco) to obtain the expansion media. About 104 
CD34+CD133+ cord blood cells were plated in a 96-well round bottomed plate, in 200 
ml/well of the expansion media. Cells were transferred to a 6-well plate 4 days later, 
and fresh media were added to keep cells at 200,000 /ml one day after the transfer. 
Cells were supplemented with more fresh media 2-3 days later, in order to maintain 
them at 700,000 cells/ml and then allowed to expand until the end of the 11-day 
culture. 
2.3 Angplt5-expressing MSCs 
The human Angptl5 gene (DNA NM_178127.2) was excised from the pCMV6-XL5 
vector (Origene, Rockville, USA) using Not I, and cloned into the pLB2 lentiviral 
vector at the Not I site. The resulting vector encodes both Angplt5 and GFP under the 
same EF1a promoter (provided by Dr. Patrick Stern of Massachusetts Institute of 
Technology). To produce lentiviruses, 293FT cells were co-transfected with lentiviral 
vectors, the HIV-1 packaging vector Delta8.9 and the VSVG vector. Supernatants 




ultracentrifugation at 25,000g for 90 min, and frozen until use. Lentivirus titers were 
107-108 /mL based on GFP expression in 293FT cells.  
Human MSCs from the BM of adult donors were purchased commercially (Lonza or 
Stem Cell Technologies). MSCs were cultured in MesenCult MSC Basal Medium and 
Mesenchymal Stem Cell Stimulatory Supplements (Stem Cell Technologies, 
Vancouver) at a density of 5,000-6,000 cells per cm2 in a T175 flask, and passaged 
before reaching 70% confluence. MSCs from 2nd to 4th passages were transduced 
with a lentiviral vector (pLB2) expressing GFP alone or both GFP and Angplt5 at 
MOI of 5. Four to five days post-transduction, 30-45% of cells were GFP+ by flow 
cytometry analysis. The mixture of transduced and non-transduced MSCs were 
expanded and used for co-cultures. 
2.4 Co-culture of cord blood CD34+CD133+ cells 
MSC-A5 or MSC-GFP was plated in a 24-well plate at 5 x 104 cells/well overnight. 
CD34+CD133+ cord blood cells were added to the culture at a cord blood cell-to-MSC 
ratio of 1:5 (i.e., 104 cord blood cells for 5x104 of pre-plated MSCs per well). The 
expansion media was used for co-culture except for the addition of Angptl5. The 
initial volume of culture media was adjusted to 300 µl/well, and fresh media were 
added every 2 days starting on the 3rd day of culture. At different time points of the 
culture, hematopoietic cells were resuspended by carefully pipetting 5-7 times 
(avoiding the detachment of the MSCs), counted and analyzed by flow cytometry to 
obtain the total cell number and the number of DP cells. After 11 or 14 days of 
culture, hematopoietic cells were resuspended thoroughly (to loosen strongly attached 




2.5 Mice and intracardiac injection 
NSG mice were obtained from the Jackson Laboratory and maintained under specific 
pathogen-free conditions in the animal facilities at Massachusetts Institute of 
Technology, National University of Singapore and Nanyang Technological 
University. Pups within 48 h of birth were sublethally irradiated (100 rad) using a 
Cesium source, and engrafted with either expanded or unexpanded cells by 
intracardiac injection.  
For engraftments, either 105 purified CD34+CD133+ unexpanded or expanded cells in 
50 l were injected per recipient, or total expanded cell suspension containing 105 
CD34+CD133+ cells in 50 l were injected per recipient. All research with human 
samples and mice was performed in compliance with the institutional guidelines.  
2.6 Serial reconstitution assays   
Serial reconstitution was performed as follows: Fourteen weeks after the 
reconstitution, BM cells were harvested from both femurs and tibias of the primary 
recipients. Human CD34+ cells were stained with PE-conjugated anti-CD34 followed 
by a PE positive selection kit (Stem Cell Technologies). CD34+ cells were pooled 
from different mice reconstituted with expanded cells from the same cord blood 
donor, and then 104 cells were injected into sublethally irradiated newborn pups.  
2.7 Single cell preparation 
Single cell suspensions were prepared from the spleen and BM by standard 




pressed through a 200-gauge stainless steel mesh, and debris was removed by 
centrifugation at 50 g for 5 min. Supernatants containing MNCs were collected, 
washed in PBS, and resuspended in 40% percoll (Sigma) in RPMI medium 1640. The 
cell suspension was gently overlaid onto 70% percoll, and centrifuged at 750 g for 20 
min. MNCs were collected from the interphase, washed twice in PBS. To isolate lung 
MNCs, lungs were minced, suspended in medium containing 0.05% collagenase 
(Sigma) and 0.01% DNase I (Sigma), and incubated at 37 °C for 20 min. The lung 
samples were passed through a 200-gauge stainless steel mesh, and MNCs were 
isolated by percoll centrifugation as described above. To isolate MNCs from 
humanized mice brain, the brain was homogenized in 7 ml RPMI 1640 and added 3 
ml stock isotonic percoll to make 30% percoll. 10 ml cell suspension was gently laid 
onto 70% percoll, and centrifuged at 500 g for 30 min. MNCs were collected from the 
interphase, washed with HBSS, and centrifuged for 7 min at 500 g.  
2.8 Flow cytometry and cell sorting 
MNCs were analyzed by flow cytometry using FACScalibur, FACS-Canto or LSR II 
cytometers (Beckton Dickinson). Cell sorting of monocyte/macrophage progenitors in 
BM was performed using FACS Aria cell sorter (BD Biosciences). The following 
antibodies were used: CD45 (2D1), CD34 (581), CD38 (HIT2), CD209 (DCN46) 
from BD Biosciences; CD14 (HCD14), CD45.1 (A20), HLA-DR (L243), CD33 
(WM53), MMR (15-2), CD209 (9E9A8), CD56 (MEM-188), CD3 (HIT3a), CD19 
(HIB19), CCR5 (HEK/1/85a), CD40 (5C3), CD7 (CD7-687), CD116 (4H1), CD114 
(LMM741), CD15 (HI98), TLR2 (TL2.1), CD11c (3.9), CD11b (ICRF44), CD36 (5-
271), CD80 (2D10), CD86 (IT2.2), CD16 (3G8), CD64 (10.1), CD163 (GHI61), 




from Ebiosciences. Dead cells were excluded from analysis by DAPI staining. 
Analyses were performed with the FACS Diva (BD Biosciences) or FlowJo (TreeStar 
Inc).  
2.9 Immunization and ELISPOT assay 
Sixteen weeks after engraftment, mice were immunized intraperitoneally (i.p.) with 
10 l of TT vaccine adsorbed on hydrated aluminum hydroxide (Teabag, Sanofi 
Pasteur, France) diluted in 90 l PBS, representing 1/50 of the recommended 
vaccination dose for a human adult. Mice were boosted twice with the same dose at 
three-week intervals. Two weeks after the third immunization, mice were sacrificed 
and the frequencies of IFN- secreting cells in the spleen were measured by 
ELISPOT assay (Ebiosciences, San Diego, CA). Briefly, single cell suspensions were 
prepared from spleens, counted and analyzed by flow cytometry for the frequency 
of human CD3+ T cells. 5x105 CD3+ cells were plated per well in a 96-well ﬂat-
bottomed plate (Multiscreen-IP, Millipore, MA, USA) that was coated overnight at 4 
°C with anti-IFN- monoclonal antibody. For T cell stimulation, 10 ng/ml of PMA 
or 0.5 mg/ml of the tetanus toxin peptide (830-843) (Genscript, USA) were added to 
the culture. After 48 hours of incubation at 37 °C, 5% CO2, IFN- immunospots 
were detected according to the manufacturer’s instructions. The spots were counted 
using an ImmunoSpot S5 Versa Analyzer (Cellular Technology Ltd. Ohio, USA) and 




2.10 Hydrodynamic injections 
pcDNA3.1 (+) vector was used to clone human cytokine genes. Plasmid DNA was 
prepared by Maxi-prep Kit (Promega) with endotoxin removal. For hydrodynamic 
injection, 50 g plasmid of each cytokine gene in 2 ml PBS was injected into mice 
older than 8 weeks within 7 seconds using a 27-gauge needle.  
2.11 In vitro differentiation assay and colony-forming unit (CFU) -
assay 
BM MNCs were flushed out from tibias of 12-week old humanized mice. Sorted 
monocyte/macrophage progenitors from BM MNCs were cultured in RPMI 1640, 
10% FCS, supplemented with 50 ng/ml M-CSF for macrophage differentiation or 50 
ng/ml GM-CSF, 50 ng/ml IL-4 for DC differentiation. All cytokines were purchased 
from R&D Systems.  
Sorted monocyte/macrophage progenitors were plated at 2000, 5000, 10000 cells per 
dish in complete MethoCult media (MethoCult H4435 enriched; Stem Cell 
Technologies) according to the product manual. Cells were incubated in 35 mm 
culture dishes at 37 °C with 5% CO2. The numbers of colonies were counted under a 
stereomicroscope after 14 days in culture.  
2.12 RNA extraction and real-time PCR 
Total RNA was extracted from lysed tissues or cells with the RNeasy Plus Mini kit 
(Qiagen) according to manufacturer’s instructions. 1 g of RNA was used for cDNA 




PCR was performed with the CFX96 Real-Time System (Bio-rad) with self-designed 
primers (supplementary Table 1). Expression values were calculated by the 
comparative threshold cycle method, and normalized to mouse L32 or human 
GAPDH.  
2.13 Histology and Giemsa staining 
For histology, each mouse was intracardiacally perfused with saline buffer for 10 min. 
Organs were harvested, placed in disposable molds, immersed in OCT (the 
embedding compound) and flash frozen in liquid nitrogen. The blocks were stored at -
80 °C and cut at 10 m per section in histology laboratory at National University of 
Singapore. 
Hematoxylin and eosin (H&E) staining was performed on formalin-fixed, frozen 
spleen sections. Immunofluorescence staining was performed on 75% acetone/25% 
ethanol fixed, frozen spleen sections. Monoclonal antibody to CD20 (L26, Abcam, 
UK), CD68 antibody (KP1, Abcam), mouse CD68 antibody (FA-11, Abcam), and 
polyclonal antibodies to CD3 (Abcam) were used as primary antibodies. Alexa 
fluro647 donkey anti-mouse IgG (Invitrogen, USA) and Alexa fluro546 donkey anti-
rabbit IgG (Invitrogen) were used as secondary antibodies. H&E stains and 
immunofluorescence stains were visualized with the MIRAX MIDI Fluorescence 
microscope (Zeiss). 
For Giemsa staining, 105 cells in 100 l 2% FCS-PBS were added to the cytospin 
cassette, and centrifuged 1000 rpm for 5 min. The cell smears on polylysine-coated 




and washed with distilled water. The stained slides were examined under a 
microscope.  
2.14 LPS challenge, influenza virus A infection and bacillus calmette-
guérin (BCG) infection 
10 g LPS (Sigma) were injected i.p. into mice. Sera were collected 0 h, 2 h and 12 
h after injection. Concentrations of human inflammatory cytokines in sera were 
analyzed by the Cytometric Bead Array System (CBA) (BD Biosciences) on LSRII 
according to the manufacturer’s instructions, and data were analyzed by FCAP Array 
software (BD Biosciences).  
300 pfu of influenza A/PR8 (H1N1) virus in 75 l PBS were administered to 
anesthetized mice via intratracheal route. Lungs were harvested at 0 h, 24 h, 48 h, and 
72 h after infection. For each mouse, the left lobe was used for the single cell 
preparation for flow cytometry analysis as described above. The superior lobe of right 
lobes was excised to extract RNA for quantitative RT-PCR analysis as described 
above. The rest of the three right lobes were weighted and homogenized in 100 mg 
tissue per 1 ml of ice-cold HBSS with 0.1% Bovine serum albumin (BSA). The lung 
homogenates were centrifuged for 10000 g, 10 min at 4 °C to collect the supernatants 
for CBA assay to measure the cytokine concentration.  
Mycobacterium bovis BCG Pasteur strain bacilli (ATCC, Manassas, VA, USA) was 
grown in 7H9 culture medium at 37 °C in an 850 cm2 polystyrene roller bottle 
(Corning) at 10 rpm. The culture reached an optical density (OD600) of 0.6, at which 
point the concentration of cells was ~5x107 /ml. Each mouse was injected i.p. with 




and the spleen was homogenized in 10 ml PBS at 0 h, 24 h, and 72 h post-infection. 
To determine the numbers of recovered viable bacilli in a culture or tissue 
homogenate, colony counting was performed with serial dilutions of the samples in 
7H9 with 100 µL of serial dilutions plated on 7H11 agar, and incubated at 37 °C with 
5% CO2. Serial dilutions and 7H11 plates were performed in triplicate, and the 
numbers of colonies on each plate counted after 4 weeks. The rest of the peritoneal 
lavage was centrifuged down to obtain cells for flow cytometry analysis, and to 
extract RNA for quantitative RT-PCR analysis as described above.  
2.15 Statistical analysis 
Data are presented as mean and standard error of the mean. The nonparametric Mann-
Whitney U test was used to analyze the differences between two groups. A P-value of 











IN VITRO EXPANSION OF HSC FOR HUMANIZED 
MICE RECONSTITUTION 
 !!!!!!!!!!!
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3.1.1 The demand for expansion of HSCs for clinical and preclinical applications 
HSCs give rise to all blood lineage cells, which function in diverse biological 
processes from immune responses to oxygen transport. Because of this unique 
property, there has been great interest in clinical and preclinical applications of HSCs. 
BM transplant is widely used to treat congenital immunodeficiencies, where the 
transfer of HSCs from normal to deficient individuals is the basis of the treatment. 
Transplantation of purified HSCs from BM, mobilized peripheral blood or umbilical 
cord blood is also a well-established treatment for certain hematologic malignancies. 
However, these treatments are often limited by the availability of HSCs in terms of 
finding suitable matching donors as well as obtaining sufficient numbers of cells.  
In preclinical applications, there has been an enormous effort in developing mice with 
human blood lineage cells (humanized mice) for studying human blood cell diseases 
and immune responses to pathogens. Construction of humanized mice requires 
engraftment of human HSCs in scid mice. With the development of a new generation 
of scid mice, such as NSG mice, which also lack NK cells, it is now possible to 
routinely construct humanized mice with high levels of human blood cell 
reconstitution. The easiest accessible source of human HSCs is cord blood. However, 
only limited numbers (105~106) of CD34+ cells can be isolated from a single cord to 
reconstitute a small number (1~10) of mice. Although HSCs from different cords can 
be used, to minimize variations due to differences in the genetic background of HSCs, 
humanized mice reconstituted with HSCs from the same source are ideally used in the 




preclinical studies requires access to sufficient numbers of human HSCs (Giassi et al., 
2008). 
3.1.2 Methods for HSC expansion 
One way to overcome the shortage of HSCs is via the expansion in vitro. In general, 
two approaches have been used: FCF culture in the presence of specific growth 
factors and co-culture with feeder cells, such as MSCs. In FCF culture, the best in 
vitro expansion of human HSCs achieved to date was reported recently by Delaney et 
al. 2010. Using a cocktail of growth factors, including human IL-3, IL-6, TPO, Flt-3 
ligand, SCF and notch ligand, total and CD34+ cells were expanded ~790 and ~200 
fold, respectively, after 17-21 days of culture, resulting in a ~16 fold expansion of 
SRCs as assayed in NSG mice (Delaney et al. 2010). Using a different combination of 
growth factors, including TPO, SCF, FGF-1, insulin growth factor binding protein 2 
(IGFBP2), and angiopoietin-like 5 (Angptl5), Zhang et al. 2010 reported a lower total 
cell expansion (~200 fold) as cells undergo senescence after 14 days. Nevertheless, a 
20-fold expansion of SRCs was observed in NOD-scid mice following a 10-11 day 
culture (Zhang et al., 2008; Zhang et al., 2006).  
Another way to expand HSCs is co-culture using a feeder layer that mimics the 
physiological microenvironment of HSCs. In particular, BM-derived MSCs have been 
shown to support the growth of HSCs from cord blood through an increased cell 
division and a better maintenance of the primitive phenotype (Walenda et al., 2009). 
MSCs from other sources, including Wharton’s jelly of umbilical cord segment 
(Wang et al., 2004), cord blood (Lee et al., 2004), amnion-derived adherent cells (In 't 
Anker et al., 2004; Kita et al., 2009), and other fetal tissues (Campagnoli et al., 2001), 




Campagnoli et al., 2001; Huang et al., 2007; Jang et al., 2006; Lee et al., 2004; 
Mizokami et al., 2009; Walenda et al., 2009; Wang et al., 2004; Wang et al., 2009). 
Many of these reports suggest that co-culture is superior to the FCF culture in terms 
of both total cell expansion and the yield of CD34+ cells when compared under the 
same culture conditions. Depending on the co-culture conditions, 80 to 800-fold 
increase in total cell numbers, and 4 to 100 fold increase in the CD34+ cells were 
reported (Alakel et al., 2009; Briquet et al. 2010; da Silva et al. 2010). The highest 
expansion was achieved by culturing HSCs with MSCs in a 3D configuration using a 
woven mesh (96 fold expansion CD34+ cells in 10 days, (Zhang et al., 2006). 
However, most studies with co-culture did not rigorously examine the scid 
repopulating activity of expanded cells in mice using long-term reconstitution, 
limiting dilution or competitive reconstitution assays. In the few cases where 
expanded cells were tested in mice, only one dose of expanded progeny was injected 
in NOD-scid mice, and reconstitution was assayed 6 weeks later in the BM (Briquet et 
al. 2010; Fei et al., 2007; Zhang et al., 2006). Another report showed a 3.4-fold 
increase of SRCs when the progeny of CD34+ cells co-cultured with human brain 
endothelial cells were injected into mice (Chute et al., 2004). 
3.1.3 Expansion of HSC in angptl5 expressing MSC co-culture  
One way to further enhance HSC expansion without promoting differentiation is to 
combine co-culture with growth factors that are shown to promote HSC maintenance 
and expansion. In this study, we co-cultured HSCs with engineered MSCs that 
express Angptl5 plus the addition of SCF, TPO, FGF1 and IGFBP2 in the media. 
Dramatically, we observed ~60 and ~150 fold expansion of CD34+ CD133+ DP cells 




same repopulating and long-term HSC properties as uncultured cells using long-term 
and serial reconstitution. In addition, mice reconstituted with the expanded HSCs 
from the co-culture have an enhanced ability to differentiate into T cells, leading to a 
more normal T cell to B cell ratio in the reconstituted mice. These results suggest that 
co-culture in the presence of selected growth factors in the media is an efficient 





3.2.1 Combination of co-culture and selected growth factors enhance expansion 
of cord blood CD34+CD133+ cells.  
To investigate whether MSCs and recently identified growth factors, such as IGFBP2 
and Angptl5, synergize in HSC expansion, we tested expansion of CD34+CD133+ 
cells on an MSC feeder layer in the presence of additional growth factors. Because 
human Angptl5 was required at high concentrations (Zhang et al, 2010) and 
expensive, we expressed it in human primary BM MSCs using a lentiviral vector. The 
Angptl5 expressing MSCs are referred to as MSC-A5. As a control, GFP-expressing 
MSCs (MSC-GFP) were constructed following the same approach. For expanding 
HSCs, purified CD133+ cord blood cells which were also CD34+, were cultured on 
top of a confluent MSC-A5 or MSC-GFP feeder layer at a ratio of 1:5 in the presence 
of SCF, FGF, IGFBP2, and TPO in the culture media. For comparison, purified 
CD133+ cells were also cultured in FCF culture, i.e., serum-free medium 
supplemented with Anglt5, SCF, FGF, IGFBP2, and TPO. At the start of the co-
culture, hematopoietic cells were observed to attach to the MSC feeder layer (Figure 
1A). By day 5, the density of hematopoietic cells was noticeably increased. By day 7, 
proliferation of hematopoietic cells was evidenced by cell density and cell counting 
(Figure 1A). By day 11, hematopoietic cells had completely covered the MSC-A5 
feeder layer (Figure 1A) and were split into fresh feeder layers and medium. To 
monitor HSC expansion, cultured cells were assayed for CD34 and CD133 expression 
since we have shown previously that SRCs reside in the CD34+CD133+ DP fraction, 
and some of the DP cells possess the long-term HSC activity (Drake et al, submitted). 







CD133+ (data not shown). After culture for 7 days, the percentage of DP cells 
decreased to ~50% in MSC-A5 or MSC-GFP co-culture, and ~30% in FCF culture 
(Figure 1B).  
The percentages continued to decrease and by day 14, they were ~15% in co-cultures 
and ~10% in FCF culture. Despite the decrease of the percentages of DP cells in the 
cultures, because the total cell numbers increased dramatically (Figure 2A), the actual 
numbers of DP cells increased ~60 fold in MSC-A5 co-culture, ~29 fold in MSC-GFP 
co-culture, and ~20 fold FCF culture at day 11 (Figure 2B). By day 14, while the 
number of DP cells did not increase significantly in the FCF culture, the number of DP 
cells increased ~150 and ~60 fold in MSC-A5 and MSC-GFP co-cultures, respectively. 
When CD34+ cells isolated from fetal liver and mobilized peripheral blood were 
cultured using the same conditions, expansion of DP cells in MSC-A5 co-culture was 
also significantly higher than that in the FCF culture (data not shown). These results 
show that the combination of MSCs and the different growth factors can support a 









3.2.2 Evaluation of contributions of feeder cells and soluble factors to the 
enhanced expansion of cord blood CD34+CD133+ cells  
To further assess the role of each of the five growth factors in the expansion of 
CD34+CD133+ cord blood cells, we performed the co-cultures without adding specific 
growth factors. For easy comparison, the expansion of DP cells in the different 
cultures was normalized to that under the standard condition where CD34+ CD133+ 
cord blood cells were co-cultured with MSC-A5 in the presence of SCF, TPO, FGF 
and IGFBP2 in the media. When CD34+CD133+ cord blood cells were co-cultured 
with MSC-A5 without the addition of any of the growth factors, they did not expand at 
all (Figure 3). Addition of SCF and TPO, which are well-established HSC growth 
factors and broadly used together (Liu et al., 1999; Ohmizono et al., 1997), into the 
above co-culture led to expansion of DP cells, reaching 19% of that obtained under the 
standard condition. With further addition of FGF or IGFBP2, the relative expansion 
was 36% and 61%, respectively. Without exogenously added Angplt5 (co-culture with 
MSC-GFP in the presence of SCF, TPO, FGF, and IGFBP2), the relative expansion 
was 43%. These results suggest that all five growth factors contribute to the expansion 









3.2.3 Expanded CD34+CD133+ cells give rise to multiple lineages of blood cells in 
NSG mice  
We tested the ability of expanded cells from the co-cultures to reconstitute different 
lineages of human blood cells in NSG mice. CD34+CD133+ cord blood cells were 
either expanded in the MSC-A5 co-culture or the FCF culture for 11 days. Total 
expanded cells, containing 105 DP cells, were engrafted into sublethally irradiated 
NSG newborn pups. Fourteen weeks later, the presence of different human blood 
lineage cells in the peripheral blood, spleen and BM were analyzed by flow cytometry. 
Among various human blood lineage cells analyzed, T cells (CD3+), B-lineage cells 
(CD19+ or CD19+IgM+), macrophages (CD14+CD33+), myeloid precursor cells 
(CD33+), hematopoietic stem/precursor cells (CD34+ or CD34+CD133+), DCs 
(CD11c+ HLA-DR+), neutrophils (CD15+), and NK cells (CD56+) were detected in the 
blood, spleen or BM (Figure 4 and data not shown). Importantly, the levels of various 
human cell reconstitution, both in terms of median percentage and the range among 
different recipient mice, were similar regardless of the conditions used to expand 
CD34+CD133+ cord blood cells (Table 1), except significantly higher percentages of 
CD3+ T cells were observed in the blood and spleen of recipient mice that were 
injected with cells from MSC-A5 co-culture than the FCF culture (p<0.05). H&E 
staining revealed a restoration of the splenic architecture with the appearance of the 
white pulp in mice reconstituted with co-cultured cells, but not in unreconstituted NSG 
mice (Figure 5). Furthermore, T cells and B cells were found in the same follicles, with 
CD3+ T cells residing predominantly in the inner region of the follicles, whereas 
CD20+ B cells resided in the outer region of the follicle. These results suggest that 
expanded cells from the co-cultures are capable of differentiating into multiple 















3.2.4 Expanded cells are capable of stable long-term and efficient secondary 
reconstitution! 
The expanded cells were tested for their ability to give rise to stable long-term 
reconstitution in NSG recipients. Following 11-day expansion in either MSC-A5 co-
culture or FCF culture, expanded cells were transferred into sublethally irradiated 
newborn NSG pups. By 12 weeks following engraftment, the percentages of human 
leukocytes in the blood were less than 50% (Figure 6A). These percentages increased 
slightly or were maintained at 24 weeks after engraftment (Figure 6A, B). No 
difference in reconstitution was observed between expanded cells from MSC-A5 co-
culture or FCF culture in the blood and spleen (Figure 6A). The level of T cell 
reconstitution in both blood and spleen was higher with expanded cells from co-culture 
than FCF culture (data not shown). These results suggest that expanded cells from both 
protocols possess similar levels of long-term reconstitution activity. 
We also assessed the presence of long-term HSC activity in the expanded cell 
population by serial transfer. Expanded cells from day 11 MSC-A5 co-culture were 
transferred into irradiated NSG pups. Fourteen weeks after engraftment, human 
CD34+ cells were magnetically enriched from the BM of primary recipient mice, and 
injected into sublethally irradiated adult NSG mice. Twelve to 16 weeks after, BM 
cells of the secondary recipient mice were analyzed by flow cytometry for human and 
mouse CD45+ cells. Among the 14 secondary recipient mice, 11 had 0.1-2% of 







other two had ~0.03%. A representative mouse is shown in Figure C. These data show 
that the expanded CD34+CD133+ cells from MSC-A5 co-culture retain a secondary 
reconstitution potential, suggesting the presence of long-term HSC activity.  
3.2.5 Human T cells are functional in the reconstituted mice  
The increased T cell development with co-culture expanded DP cells prompted us to 
test if the T cells are functional. Similarly reconstituted mice with expanded cells from 
either co-culture or FCF culture were immunized with TT and boosted twice at an 
interval of 3 weeks. Two weeks after the last immunization, splenocytes were assayed 
for IFN- expression by ELISPOT assay. Without immunization, significant numbers 
of IFN- immunospot were detected only if splenocytes were stimulated with PMA 
during the assay, regardless of whether the cells were from mice reconstituted with 
expanded cells from the co-culture or the FCF culture (Figure 7A). Similarly, 
significant numbers of spots were detected in PMA-stimulated splenocytes from 
immunized mice, regardless whether reconstituted with expanded cells from the co-
culture or the FCF culture. As expected, with TT stimulation of splenocytes in the 
culture, significant numbers of spots were detected only in TT immunized mice. 
However, the average numbers of spots were significantly higher in mice reconstituted 
with cells from the co-culture than the FCF culture (104 ± 37 vs. 22 ± 14, P < 0.005). 
These results suggest that enhanced T cell development leads to an enhanced T cell 








Here we report an improved method to expand HSCs from umbilical cord blood by 
combining the HSC growth factors recently identified by Zhang et al. 2010 with a 
BM-derived MSC feeder layer. We reasoned that by adding the growth factors into 
the co-cultures it might be possible to further enhance HSC expansion while 
minimizing differentiation. By all measures, this approach worked significantly better 
than the FCF culture or co-culture without the selected growth factors. In our 
experiments, CD34+ CD133+ cells from the same cord blood donor were expanded 
using the three different conditions, and the fold expansion of DP cells was monitored 
because we have shown previously that the SRCs reside in the DP cell fraction. 
Compared to FCF culture, which expanded DP cells 20-25 fold during 11-14 days, 
co-culture with MSC-A5 expanded DP cells 60-150 fold, whereas co-culture without 
Angptl5 (MSC-GFP) expanded DP cells 28-60 fold during the same period. These 
observations were further supported by results from experiments where different 
growth factors were added into the MSC-GFP co-culture. It is noticeable that the co-
culture system expanded the SRCs, as measured by CD34 and CD133 expression, 
faster than FCF cultures and retained a higher proportion of CD34+ (47% vs. 20% on 
day 14) and CD34+CD133+ cells (15% vs. 9% on day 14), producing 150 fold of 
expansion of DP cells by day 14. These findings suggest that both MSCs and the 
selected growth factors, especially Angptl5 and IGFBP2, contribute significantly to 
the expansion of CD34+ CD133+ cord blood cells in the co-culture.  
Different from previous co-culture studies, we rigorously evaluated the reconstitution 
activity of expanded cells from the co-culture in long-term and serial reconstitution. 




reconstitution. When human CD34+ cells were isolated from the BM of primary 
recipient mice and transferred into second recipient mice, 12 of 14 recipients had 
more than 0.1% human cells in the BM 12-16 weeks later. These results suggest that 
some of the expanded cells still possess the long-term HSC activity.  
MSCs have been shown to stimulate differentiation of HSCs. With the recent 
development of the NSG mouse model that supports robust lymphoid engraftment, we 
examined the ability of the co-culture expanded cells for T and B cell reconstitution. 
While unexpanded or expanded CD34+CD133+ cells from the FCF culture give robust 
B cell but poor T cell reconstitution initially, we show that the co-culture expanded 
cells gave significantly enhanced T cell reconstitution, reaching the normal T to B cell 
ratio as in humans and mice. The observed T cell-bias was opposite to the effect 
reported by Giassi et al. (Giassi et al., 2008), further suggesting a critical role of MSC 
in regulating differentiation in the co-culture. Given that we did not observe any 
reduction in long-term repopulation capacity, the T cell-biased reconstitution suggests 
that MSCs also support progenitor cell expansion. Furthermore, the expanded T cell 
population significantly enhanced the antigen-specific T cell response in mice 
reconstituted with co-culture expanded cord blood cells as assayed by ELISPOT. 
However, whether the improvement in cytotoxic T cell response is due to the 
increased T cell number or improved functionality is still not known.  
In both clinic and laboratory, the supply of HSCs is limiting with little prospect of 
finding significant new sources of cells. Strategies to make the existing sources of 
cells go further are essential for both improving treatments of hematologic 
malignancies, and our understanding of human hematology and immunology. While 
progress is being made with strategies to improve delivery of stem cells, ex vivo 




transfer of unexpanded and expanded cells from different donors together 
significantly reduced the period of neturopenia following transplantation (Delaney et 
al. 2010). However, over time the graft was universally dominated by unexpanded 
cells in all patients. In another clinical trial, HSCs from umbilical cord blood were 
expanded by approximately 12-fold on donor-related MSCs and injected in 6 cancer 
patients. Five out of the six patients were in complete remission after one year of the 
engraftment (Kelly et al., 2009). The improved approach for expanding HSCs 
reported here not only solves one bottleneck for the humanized mice research field to 
generate large numbers of humanized mice from the same HSC source for large-scale 













HUMAN M-CSF MOBILIZES PROMONOCYTES IN BM 
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4.1 Introduction  
4.1.1 The problem of human monocyte/macrophage development in NSG mice 
A major avenue for improvement of current humanized mice is to generate mice with 
a functional immune system of human origin. To achieve this, a complete 
hematopoietic system is a prerequisite. In NSG mice, human T and B cells can stably 
reconstitute the mice for more than one year while NK cell reconstitution, which was 
very poor in NSG mice, is also improved by expression of human IL-15 and Flt3 (or 
flk-2) (Chen et al., 2009; Hiramatsu et al., 2003; Ishikawa et al., 2005; Shultz et al., 
2005; Yahata et al., 2002). Nevertheless, myeloid lineage cells, such as 
monocytes/macrophages, granulocytes, megakaryocytes and erythrocytes, are poorly 
developed and maintained in humanized mice (Ishikawa et al., 2005; Legrand et al., 
2006; Manz, 2007; Shultz et al., 2007). The defect of human myeloid development in 
NSG mice has been speculated to be the result of an inefficient myelopoiesis, and a 
relatively intact mouse myeloid compartment (Macchiarini et al., 2005; Manz, 2007; 
Shultz et al., 2007). In view of the fact that myeloid cells play a vital role in oxygen 
transport (erythrocyte), blood coagulation (megakaryocytes) and development of 
efficient immunity against infectious pathogens (granulocyte and macrophages), 
generation of humanized mice with efficient human myelopoiesis is of paramount 
importance.  
4.1.2 The role of human monocytes/macrophages in immune responses  
In this part of the thesis, we will focus on correcting the defect of human 
monocyte/macrophage development in humanized mice. Monocytes/macrophages, 




The mononuclear system is derived from common myeloid precursors in BM, 
circulates in the blood as monocytes, and populates tissues as macrophages in the 
steady state and during inflammation. Monocytes function as immune effector cells, 
and do not proliferate in a steady state (Auffray et al., 2009a; Auffray et al., 2009b). 
The expression of chemokine receptors and adhesion receptors on monocytes 
facilitate their migration from blood circulation to sites of inflammation. In the course 
of migration to tissues, they produce inflammatory cytokines and differentiate into 
inflammatory DCs or macrophages. Even in the steady state, monocytes are believed 
to serve as a pool to replenish tissue macrophages and DCs (Serbina et al., 2008). 
Macrophages are resident phagocytic cells in both lymphoid and non-lymphoid 
organs. They participate not only in the initiation and resolution of immune response 
during tissue injury or infection, but also play a critical role in steady-state tissue 
homeostasis, via the clearance of apoptotic cells, and the production of growth factors 
(Geissmann et al., 2010). In addition, there is accumulating evidence that many 
diseases may be caused by dysregulated macrophage function, such as adipose tissue 
macrophages in metabolic disorders, M1-like macrophages in atherosclerosis, and 
Kupffer cells in liver fibrosis (Murray and Wynn, 2011). The study of macrophage 
biology would greatly help to develop therapies for the above diseases. Nevertheless, 
the developmental origin and the function of tissue macrophage subsets, such as 
microglia, dermal macrophages, alveolar macrophages, Kupffer cells, splenic 
marginal zone and metallophilic macrophages remain insufficiently understood 




4.1.3 Cytokines and monocyte/macrophage development 
The development of a mononuclear phagocyte system is governed by cytokines: small 
secreted proteins that promote cell-cell communication, and can act as growth and 
differentiation factors. The generation of monocytes and macrophages, and to some 
extent DCs, is dependent on cytokine M-CSF (or CSF-1), which was originally 
defined by its ability to generate macrophage colonies when added to cultures of BM 
progenitor cells in vitro (Stanley et al., 1975). Subsequent discovery of 
CSF1op/CSF1op mouse, which carried a spontaneous mutant lacking a functional Csf1 
gene, showed the indispensable role of M-CSF in the generation and maintenance of 
monocytes and tissue macrophages (Cecchini et al., 1994; Yoshida et al., 1990). At 
which point the M-CSF is critical in macrophage development is still debated (Lenzo 
et al., 2011). In the op/op mice, there is severe depletion of monocytes in circulation. 
The production of macrophage colony-forming cells and monocytic cells 
(monoblasts, promonocytes and monocytes) is also defective in BM, and various 
tissue macrophages are deficient (Felix et al., 1990a; Felix et al., 1990b; Wiktor-
Jedrzejczak et al., 1992; Wiktor-Jedrzejczak et al., 1991; Wiktor-Jedrzejczak et al., 
1982). This evidence together suggests that the absence of M-CSF causes the 
macrophage development to be blocked at an early myeloid progenitor stage. 
However, a few immature macrophages are present in op/op mice, which are believed 
to be M-CSF independent macrophages derived from granulocyte/macrophage 
colony-forming cells or earlier hematopoietic cells with the help from GM-CSF and 
IL-34 (Naito et al., 1991; Wei et al., 2010; Wiktor-Jedrzejczak et al., 1992). Another 
important cytokine for monocyte/macrophage development is GM-CSF, which was 
also found in the in vitro BM cell culture to generate both granulocyte and 




compromise the steady-state myelopoiesis and most tissue macrophage populations. 
The major phenomenon observed in GM-CSF deficient mice is the pulmonary 
alveolar proteinosis because of a defect in alveolar macrophage maturation (Stanley et 
al., 1994). Taken together, this evidence supports the argument that M-CSF plays a 
major role in monocyte/macrophage development and acts at the early stages of 
myeloid development, whereas the role of M-CSF, GM-CSF and IL-34 in human 
macrophage development is still unclear due to the lack of a proper model to study. 
4.1.4 Past efforts to improve monocytes/macrophages in humanized mice 
Of note, the understanding of mouse tissue resident macrophages does not often apply 
to human macrophages because homotropic pathogens are predominantly or solely 
found in humans, and different sets of molecules are employed by human 
macrophages to control infections (Murray and Wynn, 2011). To translate knowledge 
obtained from animal models to better understand human macrophages and their role 
in associated diseases, humanized mice may offer an important in vivo readout if the 
engraftment and function of human macrophages reach a comparable level to humans. 
Moreover, the “human” innate and adaptive immune responses in current humanized 
mice, which are measured without the participation of human macrophages, are not a 
natural response as it is in humans and may hinder the application of humanized mice 
for preclinical testing. Hence, there is a great need to improve the reconstitution of 
tissue resident macrophages in humanized mice. 
As certain murine cytokines critical for development of monocytes/macrophages, 
such as M-CSF, GM-CSF and IL-34, do not act on human counterparts (Fixe and 
Praloran, 1997; Ginhoux and Merad, 2010; Manz, 2007; Metcalf, 1986; Stevenson 




introduce human GM-CSF or M-CSF into humanized mice and significantly 
improved the reconstitution of human DCs and monocytes in peripheral blood and 
various organs, respectively (Chen et al., 2009). However, to what extent this 
treatment would restore the population and function of human tissue macrophages are 
still uncharacterized. Billerbeck et al. 2011 created NSG mice transgenically 
expressing human SCF, GM-CSF and IL-3 (NSG-SGM3), and then humanized them 
with CD34+ human fetal liver (FL) cells (Billerbeck et al., 2011). Although the 
frequencies were elevated, human myeloid cells were still mostly found in the BM, 
but few in the peripheral organs. Subsequently, several other groups created human 
GM-CSF/IL-3 or M-CSF gene knock-in humanized mice to improve the engraftment 
of monocytes/macrophages (Rathinam et al., 2011; Willinger et al., 2011). Despite 
much progress that has been made in improving the engraftment of human monocytes 
in peripheral blood of these cytokine-supplemented mice, there is lack of direct 
evidence of improved reconstitution and function of human tissue macrophages. 
Moreover, a clear explanation of the problem of monocytes/macrophage development 
in humanized mice is still lacking. 
4.1.5 Improvements of human macrophage reconstitution and immune function 
in humanized mice 
Based on the hypothesis that human monocyte/macrophage development is impaired 
by cytokine cross-reactivity, we analyzed the BM of humanized mice and identified a 
unique large population of SSChighCD14lowCD45+ human monocyte precursors. These 
cells could be differentiated in vitro and in vivo to monocytes and macrophages when 
cultured with human GM-CSF or M-CSF. By hydrodynamic injection of plasmids 




macrophages in various organs in humanized mice compared to untreated mice. 
Furthermore, enhanced engraftment and functionality of monocytes/macrophages 
leads to substantial improvement in human immune responses in M-CSF-treated mice 





4.2.1 Human monocyte and macrophage development is blocked in BM of 
humanized NSG mice 
To generate humanized mice, sublethally irradiated newborn pups were injected via 
intracardiac route with CD34+ HSCs isolated from human FL. Twelve weeks after 
injection, human monocyte and macrophage reconstitution was examined in 
peripheral blood and various organs. Among human CD45+ MNCs, the levels of 
CD14+CD11b+ monocytes ranged from 0% to 6% in blood. Although monocytes were 
detected in blood and organs, their frequency was relatively lower than that in 
corresponding human tissues and murine tissues (Figure 8A) (Fluks, 1981). To 
determine the frequency of tissue resident macrophages, CD14+CD68+ cells were 
examined in spleen, BM, lung and liver (Figure 8B). Most CD14+ cells did not 
express the macrophage marker CD68 in the spleen, lung and liver. This suggests that 
human monocytes cannot efficiently differentiate into macrophage in humanized 
mice.  
One important observation is that a large CD14low population was present only in BM 
but not in other organs or blood. Along with this observation, we also found a unique 
population with high side scatter (SSC) in BM (Figure 9A). The average number of 
this population per mouse BM (one tibia) was ~3 million, which is ~10% of human 
cells in BM. To find out the relationship between these two populations, the CD14low 
population was gated, and traced back to forward and side scatter characteristics 
(FSC/SSC) gating. As a result, >80% of CD14low cells are SSChigh cells (Figure 9B). 




promonocytes (van Lochem et al., 2004), we hypothesized that the monocyte 
development in BM stopped at the promonocyte stage and hence monocyte could not 










4.2.2 Human myeloid differentiation stops at monoblast to promonocyte stage in 
the BM of humanized mice 
To further confirm the developmental stage of this unique population in BM, SSChigh 
cells were purified (>90%) to check their morphology by Giemsa staining (Figure 
10A). The majority of these cells had an oval or indented nucleus with several 
nucleoli (Figure 10B). This is in agreement with the high SSC and suggests they are 
promonocytes. In addition, the phenotype of these cells was CD45+CD34-
CD13+CD33+CD15+CD11b+CD14low, which resembled the surface expression as 
promonocytes (van Lochem et al., 2004) (Figure 10C). Quantitative RT-PCR analysis 
of these cells also showed that they expressed myeloid genes (e.g. EGR-1, PU.1, 
VDR and LZM), and the levels of expression were lower than the levels in CD14+ 
cord blood monocytes (Figure 11). This suggests that these BM CD14low cells belong 
to the myeloid lineage. Their low expression of the early myeloid commitment gene 
c-myb, and the expression of the differentiation gene C/EBP further restrained the 
developmental progression to post-monoblast stage (Valledor et al., 1998). As 
myeloid cells are known to down-regulate the expression of MPO after maturing to 
monocytes (Lubbert et al., 1996), the relatively high expression of MPO suggests 
these cells are still at an immature stage. Based on these results, we conclude these 
immature cells in BM are CD14lowSSChigh promonocytes. Hence, the accumulation of 
promonocytes and lack of mature human macrophages in peripheral blood strongly 
suggests that human monocyte/macrophage development in humanized mice may be 












4.2.3 Human monocyte/macrophage development is restored by cytokine 
treatment 
Human monocyte/macrophage lineage commitment and maturation rely on serial sets 
of cytokines. GM-CSF, M-CSF and IL-34 are one set playing a critical role in the 
development of granulocyte and monocyte precursor (CFU-GM) (Valledor et al., 
1998). However, mouse GM-CSF, M-CSF and IL-34 are not cross-species active on 
human cells (Manz, 2007). Hence, we also performed the colony-forming cell assay 
to obtain information on the frequency and types of progenitors present in the SSChigh 
population, and their ability to proliferate and differentiate when supplemented with 
human cytokines. Cells were plated in enriched MethoCult, which supports the 
optimal growth of erythroid progenitors, including colony-forming-unit-erythroid 




granulocyte/macrophage progenitors, including colony-forming-unit-granulocyte 
macrophage (CFU-GM); colony-forming-unit-granulocyte (CFU-G) and colony-
forming-unit-macrophage (CFU-M); and multipotential-colony-forming-unit-
granulocyte, erythroid, macrophage, megakaryocyte (CFU-GEMM). Two weeks later, 
only CFU-M was detected under the microscopy with a frequency of 1/220 (Figure 
12B). Many small CFU-M like colonies with less than 20 cells were observed but not 
counted. These colonies may be derive from monoblasts and promonocytes, which 
have limited proliferation potential. Hence, it is likely that SSChigh population is 





The finding that SSChigh population comprised monocyte/macrophage progenitors, 
and that human monocytes developed in vitro in the presence of M-CSF and GM-
CSF/IL-4 suggests that these human cytokines may also drive the differentiation of 
SSChigh populations to mature monocytes in vivo. To introduce human cytokines into 
mice, we used hydrodynamic delivery of cytokine-encoding plasmids. 7 days after a 
single injection of 50 µg human M-CSF or GM-CSF encoding plasmids, 
promonocytes disappeared and abundant human CD11b+ monocytes were presented 
in blood, while promonocytes and blood monocytes remained unchanged in untreated 
control mice and in mice injected with human IL-4 encoding plasmids (Figure 13). 
The percentages of human CD11b+ monocytes also significantly increased in the 
spleen, BM, liver and lung in M-CSF or GM-CSF treated mice, but not in IL-4 treated 
mice (Figure 14A). Human monocytes/macrophages induced by M-CSF are known to 
express high CD14, whilst GM-CSF or IL-4 stimulated monocytes down-regulate the 
expression CD14 and exhibit accessory cell functions like DCs (Liu et al., 2001; 
Ruppert et al., 1991; Shalhoub et al., 2011). The same phenomenon was observed in 
our cytokine-treated humanized mice. To further explore whether the increased 
monocytes in M-CSF and GM-CSF treated mice were macrophages, we purified 
CD45+CD11b+ cells from splenocytes of GM-CSF treated mice and M-CSF treated 
mice, and stained these cells with Giemsa. These sorted cells from both GM-CSF 
treated mice and M-CSF treated mice exhibited typical macrophage morphology, i.e. 
large in size, round shape and heavily vacuolated (Figure 14B). Based on the results 
obtained, we found promonocytes could be mobilized by GM-CSF or M-CSF 








4.2.4 Human tissue resident macrophages are generated in M-CSF treated mice 
Since CD14+CD11b+ monocytes/macrophages were significantly increased in M-CSF 
treated mice, and the sorted CD11b+ cells exhibited macrophage morphology in both 
GM-CSF treated mice and M-CSF treated mice, we further analyzed the M-CSF 
treated mice for tissue resident macrophages. M-CSF treated mice were perfused with 
saline, and their organs including brain, spleen, lung and liver were harvested. Single 
cell suspensions were prepared, and stained with tissue resident macrophage marker 
CD163 and CD68. Interestingly, untreated humanized mice did not reconstitute well 
with CD14+ cells, and also most of CD14+ cells did not express the macrophage 
marker CD68 and CD163. These results suggest that monocytes/macrophages 
naturally developed in humanized mice cannot mature into tissue resident 
macrophages. As expected, the frequencies of human CD14+CD68+ and 
CD14+CD163+ cells were significantly increased in all organs of M-CSF treated mice 
(Figure 15).  
To further support the findings that tissue resident macrophages can develop in M-
CSF treated mice, histology analysis of liver, lung and kidney was performed on 
saline-perfused M-CSF treated mice. Consistent with the flow cytometry data, 
untreated humanized mice showed no human CD68+ cells in the examined organs, but 
a considerable number of mouse CD68+ cells were observed in the lung and liver 
(Figure 16A). In contrast, the lung and liver of M-CSF treated mice were substantially 
reconstituted with human CD68+ macrophages (Figure 16B). Of note, these M-CSF 
induced macrophages selectively reconstituted in the liver and lung, but not in the 
kidney. Their frequency and distribution patterns were similar to their mouse 




successfully reconstitute M-CSF treated mice and were strategically located in 








4.2.5 Human inflammatory responses are enhanced in M-CSF treated mice 
To investigate whether the induced monocytes and tissue macrophages in M-CSF 
treated mice were functional, we injected LPS i.p. to induce systemic inflammation. 2 
hours and 12 hours after injection, mice were bled and the serum levels of human 
proinflammatory cytokines were determined by CBA assay. Consistent with the 
increased frequencies of monocytes and macrophages in M-CSF treated mice, 
significantly elevated levels of IL-6, TNF-, IL-10, IL-1 and IL-8 were detected in 
the M-CSF treated mice (Figure 17). Of note, the basal levels of these cytokines were 
the same between M-CSF treated mice and untreated mice, which indicated the 
quiescent status of newly generated monocytes and macrophages in M-CSF treated 
mice. Overall, human inflammatory responses mediated by human monocytes and 











4.2.6 M-CSF treated mice mount enhanced immune response against influenza A 
virus 
After we have shown the presence of tissue resident macrophages and their responses 
to LPS, we further used influenza A virus infection as a model to test whether the 
human alveolar macrophages can provide innate immunity to a natural pathogen in 
M-CSF treated mice. We infected mice intratracheally with 300 pfu influenza A/PR8 
(H1N1) virus, and sacrificed them at 24 h, 48 h, and 72 h post-infection for various 
tests. The influenza virus RNA was examined at each time-point by quantitative PCR 
of lung homogenates and normalized to mouse gene L32 expression. The viral levels 
were significantly lower in M-CSF treated mice than untreated mice during the course 
of infection (Figure 18A). However, the difference of virus load between M-CSF 
treated mice and untreated mice became smaller as the infection progressed. To 
investigate if the decreased virus load was the results of improved human macrophage 
reconstitution in the lung, we carried out several experiments to assay human 
macrophage response to influenza infection. First, the human alveolar macrophages 
obtained from M-CSF treated mice displayed enhanced activation as assessed by the 
upregulation of CD80 costimulatory molecules at 24 h post-infection (Figure 18B). 
Second, in addition to the increased frequency of human alveolar macrophages (as 
demonstrated in Figure 15 and Figure 16), their absolute numbers were significantly 
higher throughout the course of infection (Figure 18C). Third, consistent with the 
increased number and functionality of alveolar macrophages in M-CSF treated mice, 
significant levels of proinflammatory cytokines, such as IL-6, TNF- and IL-1, 
were detected both at protein and RNA levels in lung homogenates between 24 h and 
72 h post-infection in M-CSF treated mice (Figure 19). In contrast, untreated mice 




influenza A infection. Similarly, as in LPS condition, the fact that only basal levels of 
proinflammatory cytokines were detected before infection supported that alveolar 
macrophages were in resting status in M-CSF treated mice. Taken together, these data 
show that M-CSF treated mice can exhibit enhanced immune response against 













Other interesting results were observed in influenza infected M-CSF treated mice. 
Unlike LPS stimulated human macrophages that secreted IL-10 into serum, human 
IL-10 protein was not detected both in lung homogenate and serum samples of M-
CSF treated and untreated mice after influenza infection (data not shown). However, 
mRNA expression of human IL-10 showed a higher level and an increasing trend in 
M-CSF treated mice compared to untreated mice (Figure 20A). Activated antigen 
specific T cells and tissue resident macrophages are the main producers of IL-10 
during influenza virus infection to suppress the inflammation and prevent injury to 
tissue. Since the specific role of IL-10 in the acute influenza infection is still unclear, 
M-CSF treated mice may offer a tool to study the regulation and function of this 
cytokine. Furthermore, since alveolar macrophages are the main type-I IFN producer 
cells after infection with pulmonary viruses, we also measured the IFN- mRNA in 
lung homogenate. M-CSF treated mice had a steadily increasing trend of human IFN-
 mRNA expression during the course of infection compared to untreated mice 
(Figure 20B) (Kumagai et al., 2007). During influenza A virus infection, macrophages 
function also as accessory cells by producing chemokines and cytokines to promote T 
cell responses to clear the viruses. In M-CSF treated mice, an increasing trend of 
human IL-12 mRNA expression correlated with the increased production of IFN- 
mRNA most likely because macrophages secrete IL-12 to stimulate the production of 
IFN- by NK cells and cytotoxic T cells (Desmedt et al., 1998; Murray and Wynn, 
2011) (Figure 20C). In untreated mice, both IL-12 and IFN- production decreased 

















4.2.7 Human peritoneal macrophages are recruited during Mycobacterium 
infection in M-CSF treated mice 
Macrophages are critical components of the innate and adaptive immune responses to 
bacterial pathogens. Infection of mice with the intracellular bacterium BCG via the 
i.p. route has served as a classic system for the study of macrophage activation 
(Hamerman and Aderem, 2001). We have demonstrated the systemic responses of 
monocytes and macrophages to LPS challenge, and the local response of tissue 
resident macrophages to influenza A virus infection. Here, we took the advantage of 
BCG infection as a model to test the ability of monocytes to migrate to inflammatory 
sites and to differentiate into activated macrophages. 5 million CFUs of BCG were 
injected into mice. Mice were sacrificed at 24 h and 72 h post-infection. Peritoneal 
lavage and spleen homogenates were collected for BCG colony assays. Significantly 
lower numbers of BCG colony counts found in the spleen and peritoneal lavage 
samples of M-CSF treated mice (Figure 21A). Moreover, human CD14+CD11b+ 
macrophages were present only in M-CSF treated mice at 24 h post-infection (Figure 
21B). These macrophages may be derived from activated monocytes recruited from 
the peripheral blood in response to BCG stimulation. However, the majority of 
peritoneal cells were still of mouse origin (>80%) during the course of infection. We 
also extracted RNA from peritoneal cells and examined the expression of human 
inflammatory cytokines (Figure 21C). Only M-CSF treated mice showed increased 
expression of IL-6 and IL-1 at 24 h post-infection. Taken together, a proportion of 
human monocytes in M-CSF treated mice can be recruited to inflammatory sites to 










The ability to study human hematopoiesis with in vivo settings is one of the 
advantages of humanized mice. Given that cytokines are important for human 
monocyte/macrophage development (e.g. M-CSF, GM-CSF and IL-34), and are 
species-specific (Manz, 2007; Wei et al., 2010), humanized mice may be regarded as 
a ‘human knockout model’ to study the impact of these cytokines. GM-CSF induces 
proliferation and differentiation of intermediate myeloid precursors, while M-CSF 
induces not only the proliferation and differentiation of late myeloid precursors but 
also the maturation of monocytes into macrophages (Ogawa, 1993). IL-34 increases 
monocytes viability, induces macrophage proliferation, and synergized with other 
cytokines to generate macrophages and osteoclasts from cultured progenitors. Based 
on the functions of these three cytokines, human myelogenesis would stop at CFU-
GM or CFU-M stages. However, as described in our results, the characterization of 
humanized mice revealed that there was a unique human cell population in BM, and 
human monocyte/macrophage development was blocked mainly at the promonocyte 
stage. Hence, it would be necessary to reevaluate our knowledge obtained from 
mouse experiments and in vitro data, and human monocyte/macrophage progenitors 
might exploit other cytokines other than GM-CSF and M-CSF for differentiation to 
promonocytes in vivo.  
Studies on op/op mice, which are deficient for mouse M-CSF, reveal that the 
hematopoietic system has the capacity to use alternative mechanisms to compensate 
for the absence of M-CSF probably by the effect of GM-CSF and IL-34 (Begg et al., 




cytokines has to be presented for monocyte/macrophage development. With 
supplementation of human GM-CSF or M-CSF by hydrodynamic injection, the 
blocked development could be restored and monocytes/macrophages could be 
efficiently generated. Human monocytes/macrophages induced by M-CSF are known 
to express high CD14, whilst GM-CSF or IL-4 differentiated monocytes down-
regulate the expression of CD14 and exhibit accessory cell functions like DCs 
(Ruppert et al., 1991; Shalhoub et al., 2011). The same phenomenon was observed in 
our cytokine treated humanized mice. Absence of both M-CSF and GM-CSF would 
hinder human monocyte/macrophage development in later stages rather than early 
stages of hematopoiesis, and the ratio of expression of these 2 cytokines affects the 
homeostasis of monocytes, macrophages and DCs.  
In agreement with the indispensable role of M-CSF in generation of mouse tissue 
resident macrophages in organs from studies on op/op mice (Cecchini et al., 1994), 
various human tissue macrophages were significantly induced after M-CSF treatment. 
Previous efforts to improve human monocyte/macrophages, such as human GM-
CSF/IL-3 or M-CSF knock-in Balb/c Rag2-/-c-/- mice, have increased levels of 
alveolar macrophages and circulating monocytes compared to control mice, 
respectively (Rathinam et al., 2011; Willinger et al., 2011). However, tissue 
macrophages other than alveolar macrophages, and circulating monocytes in GM-
CSF/IL-3 knock-in mice were not significantly improved. Although high percentages 
of circulating monocytes were achieved in M-CSF knock-in mice, the highest level of 
tissue monocyte/macrophage reconstitution was still under 5% of human CD45+ cells. 
There could be several reasons for the limited improvements seen in these knock-in 
mice. First, these mice were created on Balb/c Rag2-/-c-/- mice, which do not have 




prevent high levels of reconstitution of human cells in tissues. Hence, the developing 
tissue macrophages and monocytes could be phagocytosed by mouse macrophages in 
M-CSF and GM-CSF knock-in mice. Second, M-CSF is not only produced by 
endothelial cells and fibroblasts, but also by monocytes, granulocytes. Moreover, 
mouse cells also consume human M-CSF. Poor tissue macrophage reconstitution in 
M-CSF knock-in mice may be the result of competition between human and mouse 
macrophages for the less than optimal amount of human M-CSF produced from 
mouse nonhematopoietic cells. Hence, a useful control to compare the human M-CSF 
levels in serum of knock-in mice would be the endogenous concentration of mouse 
M-CSF in serum of wild type mice rather than immunodeficient mice. As we used 
hydrodynamic injection to deliver cytokines into NSG mice, we circumvented the 
above problems confronted by knock-in mice. Although hydrodynamic injection 
provides short-term and variable levels of expression in vivo, the levels of expression 
are much higher in hydrodynamic condition compared to the levels in knock-in 
condition. This excessive amount of cytokines guarantees that both human and mouse 
monocyte and macrophages could be efficiently generated. Hence, both high levels of 
circulating monocytes and different types of tissue macrophages were induced after a 
single hydrodynamic injection of M-CSF plasmids. This method renders researchers a 
rapid approach to test the effect of one or several secreted proteins in mice. 
Furthermore, the level and duration of the expression of gene expression can be 
optimized in hydrodynamic injection by the amount of plasmids, choice of the 
promoters, and number of injections. Therefore, hydrodynamic injection of M-CSF 
encoding plasmids into NSG mice leads to high levels of human tissue resident 
macrophage reconstitution, and the tissue macrophage in NSG mice offers a unique 




development and compare the human macrophage with their cognate mouse model 
systems. This is an area with great potential, as the chasm between understanding 
human and mouse macrophages is wide.  
Along with the improved reconstitution of human monocytes and tissue macrophages, 
M-CSF treated humanized mice also exhibit significantly stronger proinflammatory 
response to LPS and enhanced protection against influenza virus and BCG infection. 
The levels of proinflammatory cytokine induced in M-CSF treated mice are ~46 fold 
and ~34 fold higher than untreated mice for IL-6 and TNF- at 2 hour post-injection, 
respectively. The LPS stimulation in current knock-in mice results in only 2-3 fold 
higher level of IL-6 than control humanized mice (Rathinam et al., 2011; Willinger et 
al., 2011). In addition, we first reported the enhanced immune response against 
influenza virus and BCG infection in humanized mice. No difference of viral load in 
the course of infection was seen between GM-CSF/IL-3 knock-in mice and control 
mice, whereas significant lower level of viral load was seen between M-CSF treated 
mice and untreated mice. In BCG infection, the numbers of BCG colonies were 
significantly lower in spleen and peritoneal of M-CSF treated mice than untreated 
control during the period measured. These improvements should be attributed to 
higher engraftment and better function of monocytes and tissue macrophages.  
Despite the presence of tissue resident macrophages and enhanced responses against 
infections, the virus burden and bacteria were still significant in M-CSF treated mice 
over the course of infection. This could imply that resident macrophages alone are 
insufficient to control the infection, and that subsequent T and B cell responses are 
needed to clear the infection (McGill et al., 2009). In M-CSF treated mice, more 




suggests functional macrophages may secrete chemokines and cytokines to attract 
more T cells and induce their differentiation into effector cells. To prove these 
hypothesis, in vitro experiments, such as mixed leukocyte reaction, need to be 
conducted to test the function of human T cells and macrophages from M-CSF treated 
mice in the future. In vivo experiments, such as immunization of tetanus toxoid and 
infection of influenza virus, also need to be carried out to test human B cell and T cell 
response in M-CSF treated mice. With information from these experiments, not only 
the functionality of M-CSF induced macrophages could be proved, the puzzle around 
human T cell activation in humanized mice may also be answered. If human 
macrophages in M-CSF treated mice were capable of stimulating human T cells in 
vitro but not in vivo, it would be necessary to investigate the impact of missing lymph 
nodes in humanized mice on efficient human immune responses. In addition, most 
cells in the peritoneal lavage after BCG infection were of mouse origin and mouse 
tissue resident macrophages were coexisting with human ones by histological 
analysis. Further improvement of this model by temporary depleting mouse 
macrophages before hydrodynamic injection may remove the undesired mouse 
macrophages and make humanized mice a promising tool to model human 
tuberculosis. 
Another limitation of this approach to improve human tissue macrophage in 
humanized mice is that several types of macrophages are M-CSF independent. The 
results have shown that macrophages in brain and kidney of humanized mice 
increased to a much less extent than macrophages in other organs. This suggests M-
CSF do not have a critical impact on the development or proliferation of these types 
of macrophages. However, this limitation could be easily overcome by injecting other 




interesting candidates to test. A more challenging and significant study would be 
improving human macrophage populations, which originate from non-hematopoietic 
progenitors, such as embryonic progenitors. Current humanized mice permit high 
levels of engraftment of human hematopoietic cells but the engraftment of cells 
derived from human tissues or embryos are generally poor. To improve the 
engraftment of macrophages, such as Langerhans cells, a subpopulation of microglia 
and Kuffer cells, which develop in the embryo before the appearance of definitive 
HSCs, humanized mice have to be further improved to achieve stable and high levels 
engraftment of nonhematopoietic cells of human origin (Ginhoux et al., 2010; 
Ginhoux and Merad, 2010; Hoeffel et al., 2012; Schulz et al., 2012).  
In summary, the findings in this study may answer a long-lasting question of 
monocyte/macrophage development in humanized mice. Hydrodynamic injection of 
human M-CSF encoding plasmids into NSG mice greatly improved the reconstitution 
of tissue resident macrophages and the related innate immune responses against 
selected human pathogens. Apart from being a model for human hematopoiesis and 
immune responses to human pathogens, the M-CSF treated mice may facilitate 
studies on the role of human macrophages in the course of tumorigenesis, 











EFFORTS TO IMPROVE  
ANTIGEN-SPECIFIC ANTIBODY RESPONSES  






This work is still in progress. LI Yan designed and performed experiments, analyzed 




To improve antibody responses in humanized mice has been an intense topic of 
research on humanized mice for many years. A humanized mouse with a proper 
humoral immune response holds promise for developing effective vaccines or even 
generating neutralizing antibodies against human pathogens for which we do not have 
good prophylaxis and therapeutics. Since de novo human T cell development and 
stable reconstitution were achieved in NSG mice, it was expected that human 
antibody response would also be greatly improved. However, the human Ig detected 
in sera of humanized mice is still mainly IgM, while very low levels of antigen-
specific IgG could be generated. As reviewed in the Introduction, the cause of this 
problem is attributed to insufficient human T cell help. Jackson Laboratory tries to 
modify the NSG mice to express one specific human HLA-DR so that human CD4 
helper T cells will be selected on human HLA-DR, and be properly activated when 
stimulated with antigen. This effort is still undergoing. Even if this approach was 
successful, the difficulty to find matched HSC would still limit the application of 
humanized mice. Hence, we tried to overcome this problem via two approaches 
detailed below:  
5.1 Expression of human CD40 ligand (CD40L) on human T cells to 
promote the maturation and proliferation of antigen-experienced B 
cells. 
The problems caused by the T cell activation may be partially remedied by expressing 
CD40L on human CD4 T cells. Human CD40 is constitutively expressed on B cells 
and other antigen-presenting cells. The CD40-CD40L interaction is essential for 
humoral responses. Upon the recognition of antigen by B cell receptor, the CD40-




B cell proliferation, germinal center formation, and Ig Isotype-switching (Grewal and 




However, CD40L expression is tightly controlled in T cells. It is only transiently 
expressed for less than 24 hours on the surface of activated T cells (Castle et al., 
1993; Grewal and Flavell, 1998). Studies have shown that CD40L on activated helper 
T cells is internalized upon encountering CD40-expressing B cells (Yellin et al., 
1994). Since human T cells are educated on mouse MHC and are difficult to be 
activated by human DCs, genetic engineering of human T cells in humanized mice to 
express CD40L may circumvent the need of T cell activation. Hence, antigen-
experienced B cells could be directly transformed into antibody-secreting cells with 
the help of CD40L expressing T cells.  
In order to express CD40L on human T cells, we constructed a lentiviral vector with 
human CD40L under the human CD4 promoter and regulatory sequences (Figure 
22A, B). We plan to infect HSCs with this lentivirus and inject infected HSCs into 
NSG mice. When mice are reconstituted with human cells, the human helper T cells 
would express CD40L to enhance the antibody production. With a proper 
immunization protocol, we could amplify the antigen-specific antibody producing B 
cells for further isolation of neutralizing antibody. Because murine CD40L, similar to 
human CD40L, has shown that the removal of the intracellular domain increases the 
time of surface expression of CD40L (Higham et al., 2010), we also constructed 
several truncations to remove the first 13-22 amino acids of the intracellular domain 
of human CD40L. These constructs successfully expressed human CD40L both on a 
cultured human T cell line (Figure 22C) and on primary human T cells isolated by 
CD3 selection from cord blood (Figure 22D). However, two issues prevented this 
project from moving forward. First, the CD4 promoter and regulatory elements did 
not restrict the expression of CD40L on CD4 T cells (Figure 22E). During in vitro 




weakly expressed CD40L. We attempted to add more regulatory elements and 
redesign the promoter, but the results were not satisfactory. Second, the expression of 
CD40L was turned off after reconstitution of lentiviral-infected HSCs into NSG mice 
(data not shown). After 2 to 3 months reconstitution with CD40L-expressing HSCs 
infected with lentivirus, we could detect human cells but without the expression of 
CD40L. The antibody isotype in these mice was still mainly IgM and low levels of 
antigen specific IgG to TT were detected after immunization. The reason for the 
apparent silencing of CD40L expression is unknown, but it may be due to the poor 
engraftment property of CD40L-expressing HSCs or the tight transcriptional 
regulation of CD40L expression in cells. To solve this problem, it is critical to obtain 
a promoter to restrict the expression of CD40L to a specific cell type or to use an 
inducible promoter to control the timing of CD40L expression.  
The limitation of this approach is the unspecific activation of B cells. Given that the 
CD40L would be forced to express on human T cells, all antigen-experienced human 
B cells could transform into antibody-producing cells. With an inducible promoter to 
control the expression of CD40L along with an immunization protocol, the targeted 
antigen-specific B cells might be able to proliferate and outgrow those unspecific 




5.2 Expression of NSG mouse MHC class II (IA-g7) on reconstituted 
human cells for proper T cell activation and antibody response 
The most obvious approach to correct the problem of human T cell selection in NSG 
mice is to replace NSG murine MHC class II gene with human HLA-DR gene. The 
human cells will thus be positively selected on mouse thymic epithelial cells 
expressing HLA-DR. However, this approach requires gene knock-in on the NSG 
background, and HLA-DR matched human HSCs to avoid graft-versus host response. 
The embryonic stem cell line for the creation of knock-in NSG mice is currently 
under development at the Jackson Laboratory. The requirement of HLA-DR matched 
HSCs also limit a wider application of these mice. An alternative approach is to 
express NSG mouse MHC class II, termed as IA-g7, on reconstituted human cells by 
lentiviral transduction of the IA-g7 gene into HSCs. In this approach, the human T 
cells are still educated on mouse MHC content. However, since human antigen-
presenting cells utilize the NSG murine MHC molecule IA-g7 to present antigen, 
human T cells would have no difficulty to recognize the signal for activation. In 
addition, no HLA mapping and matching is necessary before each injection of HSCs 
into NSG mice, and expression of the mouse IA-g7 may increase the engraftment of 







We constructed a lentiviral vector to express IA-g7 under the ubiquitous chromatin 
opening element (UCOE) promoter (Figure 23A). This promoter drives stable and 
reproducible expression of IA-g7 alpha and beta chains. We infected the human Raji 
cell line with this lentiviral construct to verify the expression of IA-g7 on human B 
cells in vitro by RT-PCR (Figure 23B). Initially, we failed to detect the expression of 
IA-g7 by an antibody specific for IA-d, which shares the same alpha chain as IA-g7 
and detects IA-g7 on NSG mouse cells. Since there was no specific antibody 
produced against IA-g7 (Rinderknecht et al., 2010), we suspected that IA-d antibody 
might not recognize IA-g7 molecule expressed by human cells. Hence, we tested 
other antibodies specific for mouse and rat MHC. Finally, we identified a clone (RT-1, 
targeted for rat MHC class I) that could recognize IA-g7 both on NSG mouse cells 
and the lentiviral-infected human B cell line (Figure 23C, D). However, this project 
encountered another problem. First, the expression of IA-g7 was very weak on HSCs 
after infection (Figure 23E). HSCs usually do not express MHC class II molecules, 
and associated accessory proteins, and this could explain the low expression of IA-g7 
on the surface of human HSCs. Hence, we proceeded to reconstitute infected HSCs 
into NSG mice. 2 to 3 months later, we could not detect any human cells expressing 
IA-g7 in these mice (data not shown). To solve this problem, we will have to verify 
the expression of IA-g7 in infected HSCs by RT-PCR. If the IA-g7 is inserted into the 
human genome but the expression is still not detected in reconstituted human cells, it 
may be the possible that the RT-1 antibody fails to recognize the IA-g7 expressed on 
primary human cells, or the expression of IA-g7 is switched off. Currently, a new 
batch of mice with IA-g7 infected HSCs is being generated for this experiment.  
Although these two projects are experiencing difficulties, efforts to find solutions to 




increase the antibody response by boosting the DCs with human GM-CSF and IL-4 in 
NSG mice (manuscript in preparation). This approach may enhance the antigen 
delivery to human T cells and B cells. However, as GM-CSF and IL-4 induced DCs 
are proinflammatory DCs, the massive production of proinflammatory cytokines and 
















6.1 Summary of thesis 
Humanized mice offer a great platform to study human diseases in vivo and to test 
new therapies. Although much progress has been made on the generation of new 
mouse strains permissive for high human cell engraftment, many critical issues still 
remain to be solved in order to bring the application of humanized mice to clinical 
and preclinical use.  
Focused on the widely used immunodeficient NSG mice, we addressed three urgent 
problems as a priority: 1) Low HSC numbers in a single unit of cord blood caused 
sample-to-sample variations, and restricted the application of humanized mice to 
large-scale preclinical studies. 2) Imbalanced human blood lineage reconstitution, 
especially monocytes/macrophages, caused poor immune responses against pathogens 
and reduced the predictive value of the human immune responses observed in 
humanized mice. 3) Human T cell selection in the mouse thymus environment 
rendered antigen-specific T cell activation difficult, and consequently poor B cell 
response and antibody production. In this thesis, we targeted these three problems, 
and found partial solutions to the first two.  
For the first issue of limited HSCs in a single unit of cord blood, we developed an 
improved culture system that combines MSCs engineered to express Angptl5 with 
other growth factors recently identified to support HSC expansion. Using this method, 
CD34+ CD133+ cord blood cells were expanded 60 and 150 fold in 11 and 14-day 
cultures, respectively. The expanded CD34+ CD133+ cells efficiently reconstituted 
secondary recipients. Furthermore, the expanded cells gave rise to multilineage 




cell reconstitution. These results demonstrate that expanded cells possess both short-
term and long-term HSC activity, and the improved approach should provide a more 
efficient method for expanding human HSCs for both clinical and preclinical 
applications.  
For the second problem of poor reconstitution and function of human 
monocytes/macrophages, we analyzed various organs of humanized mice to 
understand the root of the problem, and discovered that human monocyte/macrophage 
progenitors accumulated in the promonocyte stage. To restore the normal 
monocyte/macrophage development in vivo, we used hydrodynamic injection to 
express human cytokines in humanized mice. Mice with human M-CSF or GM-CSF 
expression significantly improved engraftment of monocytes/macrophages. In 
particular, M-CSF treated humanized mice supported the development of tissue 
resident macrophages in various organs, such as liver and lung. Moreover, M-CSF 
treated humanized mice had enhanced responses against influenza virus and BCG 
infection. Hence, the humanized mice with human tissue resident macrophages offer a 
approach for the study of human macrophages and their roles in disease progression 
in a small animal model.  
Although these two improvements in humanized NSG mice partially solved the above 
problems in principle, it is acknowledged that several key issues still exist. For 
instance, expansion of HSCs eliminates the variation among cord blood samples, but 
in vitro culture is still expensive because of the relatively high concentration and cost 
for IGFBP2. Nonetheless, if the method developed here is widely applied and is 
marketed, mass production may reduce the cost. Furthermore, the improvements of 




human myeloid compartments are still poorly reconstituted in humanized mice, such 
as neutrophils, erythrocytes and megakaryocytes.  
In this thesis, I also made two attempts at improving human IgG antibody response in 
humanized mice. In the first attempt, several lentivectors were constructed to express 
human CD40L on reconstituted human CD4 T cells. This approach planned to utilize 
the costimulatory ability of CD40L to activate antigen experienced human B cells to 
secret antibodies. However, the expression of CD40L was not restricted on T cells 
despite that the CD40L gene expression was driven by a CD4 promoter. Moreover, 
the expression of CD40L was switched off after 2-3 months reconstitution. In another 
attempt, several lentivectors were cloned to express mouse MHC class II molecule 
IA-g7 on reconstituted human cells. This approach targeted the problems of human T 
cell selection on murine MHC content and hoped that matched MHC-TCR interaction 
would enhance the human B cell activation in humanized mice. However, this 
approach encountered the similar problem of target gene silencing like CD40L 
project. These problems are currently under investigations.  
Despite room for further improvement on these problems in NSG mice, the current 
achievements on HSC expansion and macrophage reconstitution have already 
broadened the application of humanized mice to many new research areas. The bigger 
group of humanized mice created from a single donor’s HSCs would make 
humanized mice applicable to large-scale studies or preclinical test without concerns 
about the variations within the group. The tissue macrophages in NSG mice offer a 
unique and powerful tool to study the development of human monocyte/macrophage 
development, and to compare the human macrophages with their cognate mouse 
model systems. This is an area with great potential, as the chasm between our 




6.2 Future perspectives 
This thesis focused on three problems in current humanized mice, and partially solved 
two of them. For future investigations, work should continue to solve the antigen-
specific antibody response. As discussed in Chapter 5, the expression of CD40L and 
IA-g7 was successful in vitro, but could not detected in the human cells in humanized 
mice reconstituted with infected HSCs. We need to isolate human cells from these 
mice, and examine if CD40L or IA-g7 is still within the human genome after 
reconstitution. This result will guide the direction for the next steps. Once these 
technical issues are solved, and CD40L or IA-g7 strategies indeed improve the 
antigen-specific antibody response, this model may have potential for generating 
monoclonal antibodies against various exogenous substances, such as viral or 
bacterial target proteins. Such monoclonal antibodies may act as therapeutic agents 
for prevention of infections or allergies.  
Another direction to improve humanized mice is to increase the reconstitution of 
granulocytes and erythrocytes. Unlike macrophages and NK cells, the problem of 
granulocyte and erythrocyte engraftment may not be simply the result of lacking 
growth factors. Since granulocytes can only be found in the BM of humanized mice 
after cytokine treatment (Billerbeck et al., 2011; Rongvaux et al., 2011), they 
probably need serial sets of cytokines to help them further mature and migrate into the 
periphery. Moreover, transient depletion of mouse granulocytes by antibody or 
chemical treatment before adding human cytokines may provide space for human 
granulocytes to grow. For erythrocyte development, more than one month is required 
to detect the population of human erythrocytes in peripheral blood after EPO/IL-3 




development may be blocked at very early stages. If human EPO/IL-3 knock-in mice 
could be developed, the human erythrocyte reconstitution may be improved, and it 
will facilitate the study of malaria in humanized mice. Currently, human erythrocytes 
from human blood must be successively injected into the mice i.p. in order to obtain 
persistent circulating human erythrocytes in blood for Plasmodium parasites to infect.  
Recently, progress in the field of regenerative medicine has drawn the attention of the 
humanized mouse research community. Following the establishment of human 
embryonic stem cells, inducible pluripotent stem cells, and various identified adult 
tissue stem cells, artificial human organs or HSCs developed from embryonic stem 
cells or inducible pluripotent stem cells may be available. Although these techniques 
have not yet impacted the field of humanized mice, the future focus on improvements 
in humanized mice could shift from purely hematopoietic cell engraftment to artificial 
human organs and HSC-integrated systems.  
After all, a mouse is not “human”. No matter how many improvements we make, the 
results obtained from humanized mice still need to be verified by clinical studies. 
However, this does not mean our efforts are meaningless. On the contrary, the more 
alike humanized mice and humans are, the fewer resources will be wasted on failed 
drug in clinical trials, and increasing knowledge will be gained from the direct study 
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